Home     Archives     Search     Authors     About Us     Subscribe     Contact Us  

Search For:
Search In:

The i2P magazine is distributed by email on a monthly basis. Subscription is free and you can unsubscribe at any time.
Subscribe Here
Unsubscribe Here

If you have any concerns for your privacy, please read our Privacy Policy

- Issue 81: April 2009
- Issue 80: March 2009
- Issue 79: February 2009
- Issue 78: December 2008
- Issue 77: November 2008
- Issue 76: October 2008
- Issue 75: September 2008
- Issue 74: August 2008
- Issue 73: July 2008
- Issue 72: June 2008

More Archives
We are in the process of moving all of our articles to the new site.

In the meantime you can find them on the old i2P site.

6. NRT & GSK = OMS

Simon Rudderham
A Community Pharmacist Perspective

Issue 47: April 2006
Page: 1 of 1 Author's Profile | Send to a Friend | Printer Version

So we have Nictoine Replacement Therapy going into supermarkets.
If you ask GlaxoSmithKline, their hands were tied by the government, forcing them into supermarkets.
If you ask other NRT providers, no pressure was placed on them by the government.
I have previously commented on my thoughts on NRT in supermarkets, but now that only one brand and one company has launched into supermarkets, the next question is what do we do with them...

Much has been said in discussion forums about retribution, and what we are going to do with GSK.
For me, the solution is simple.
I already have a tenuous relationship with my GSK OTC rep.
This started when she brought me a whole bunch of information as to how Zovirax's MAC-P formula is what dramatically improved absorption of Aciclovir, and that I may be doing my customers a great disservice by only stocking the lower price brand.
I politely suggested that since the pricing of Zovirax, and the bulk deals, it would be cheaper for me to place an order through my local supermarket than through her, hence ruining any commission.

At the beginning of 2006, GSK did some Co-op with our store.
We did a window, and several counter units for NRT.
We have done Zantac and Panadol promotions with them also.
Panadeine pocketpack have also adorned our counter in prime position.

But no more.

The best way to hurt GSK is to limit the sale of their product.
No song and dance, no threats of war, just a cessation of prime placement of product, and a firm insistence that any promotion of any GSK product would be detrimental to our business.

It seems silly to promote their products onto the shelves of supermarkets.

Nicotine Replacement Therpay and GlaxoSmithKline = Off My Shelves.

Back to Top | Back to Home
Copyright © Computachem Services, All Rights Reserved. Published by Computachem Services, PO Box 297 Alstonville 2477 NSW Australia